Purpose: To determine certifications of visual impairment (CVIs) due to diabetic retinopathy (DR) in a region that has operated diabetic screening since 1992. Methods: A retrospective review of all CVIs due to DR was conducted, with mid-year population estimates and a diabetes prevalence model used to determine the annual incidence of certification from 2010 to 2013. For 2013, CVIs due to DR were also compared to all CVIs in the region. Results: The total number of certifications due to DR was 75; 52 were sight impaired (SI) and 23 severely sight impaired (SSI) certifications; 25% of patients had type 1, and 75% had type 2 diabetes mellitus. The mean age at time of CVI was 65.5 years. The mean duration of known diabetes was 22.0 years. The incidence of CVI due to DR ranged from 30.8 to 77.4 per million population per year between 2010 and 2013. The incidence of CVI in the diabetic population was estimated at 0.47 to 1.21 per 1000 patients per year with diabetes for 2010-2013. In 2013, DR was a main or contributing cause in 4.3% of all CVIs, but did not contribute to any SSI certifications in the working age population. Conclusion: The incidence of CVI due to DR was comparable to that reported in other regions. Nationwide, DR was the second most common cause of blindness in working age adults, but did not contribute to any SSI certifications in our population. Our results are consistent with the success of a long-standing retinal screening programme.
Introduction
Diabetic retinopathy (DR) and maculopathy are the second most common cause of blindness in working age adults in England and Wales, resulting in a significant personal, economic and societal burden (Liew et al. 2014) .
Early diabetic retinopathy is asymptomatic, and visual impairment only develops after proliferative retinopathy or macular disease has become advanced. Studies have proven the benefit of timely intervention with laser treatment (The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative DR. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. 1981; Early Treatment DRS research group. Photocoagulation for diabetic macular edema. Early Treatment DRS report number 1 1985) , and it is estimated that a screening programme in UK has the potential to save more than 400 people a year from blindness (Scanlon 2008) . Between 2003 and 2008 , UK introduced a nationwide diabetic retinopathy screening service, the National Health Service (NHS) Diabetic Eye Screening Program (DESP), with the aim of identifying treatable retinopathy at a preventable stage, and reducing the incidence of blindness from diabetic eye disease (NHS Diabetic Eye Screening Programme n.d.).
Screening for DR was first introduced in the Exeter Health Authority area in 1992. Currently, the North and Eastern Devon DESP serves the districts of Mid Devon, North Devon, East Devon and Exeter, and has provided annual DR screening for the catchment population since 2005. This study reports on the incidence of visual impairment related to diabetes in the North and Eastern Devon region between 2010 and 2013. The study also looks at trends in incidence of visual impairment certification due to diabetic retinopathy.
Patients and Methods
A retrospective review of new certifications of visual impairment (CVI) for the North and Eastern Devon population was conducted from records held at the North and Eastern DESP Office and the North Devon District Ophthalmology Department. Only CVIs with DR or maculopathy as a contributing cause were available between 1st January 2010 and 31st December 2012. Between 1st January 2013 and 31st December 2013, all new CVIs for the catchment population of North and Eastern Devon were available and included in the study.
The type of visual impairment (SI or SSI), cause of visual impairment and demographic details were recorded. Some patients had more than one cause of visual impairment documented. Data were collected on the main cause of visual impairment when this was indicated by the ophthalmologist completing the CVI form. 'Multiple pathology' was used where the completing ophthalmologist has not indicated a single main cause, either due to differing causes in the two eyes, or where there was more than one cause of visual impairment in the same eye, and the completing ophthalmologist was unable to determine which contributed more significantly to the visual loss. In these cases, the contributory causes were documented, and later combined with the main causes for analyses.
The incidence of CVI due to DR per million population was estimated by dividing the number of new CVIs in each year by the mid-year population estimates (all ages) for North and Eastern Devon that were obtained from the UK Office for National Statistics (ONS) (Office for National Statistics. Population Estimates n.d.).
The incidence of CVI due to DR per 1000 diabetic population was estimated by dividing the number of new CVIs in each year by the estimated number of people with diabetes for the Devon County area. This value was obtained by applying the diabetes prevalence model developed by the Yorkshire and Humber Public Health Observatory (YHPHO), to mid-year population estimates derived from the UK ONS. This analysis was applied only to those aged 16 years and above due to the limitations of the YHPHO diabetes prevalence model, which provides estimates of total (diagnosed and undiagnosed) diabetes prevalence only for people aged 16 years and older in UK using data from the Health Surveys for UK while taking into account age, sex, ethnic group distribution, deprivation, projected trends in obesity (Holman et al. 2011 Tests of normality were applied to the data, and since the data all complied with this assumption, continuous data (mean age at time of CVI, mean duration of diabetes at time of CVI, mean duration in screening programme before CVI, mean duration between CVI and last diabetic screening visit prior to CVI, last recorded IFCC-HbA1c, total cholesterol and creatinine in the 12 months prior to CVI) were compared with a Student's t-test, while counts (gender, type of diabetes) were compared against a chi distribution.
Linear regression analysis was applied to IFCC-HbA1c, total cholesterol and creatinine levels in the 5 years preceding CVI, as well as to the incidence of CVI due to DR per million population and per 1000 diabetic population aged 16 years and above over the four years under study. This analysis was undertaken comparing the variable under test over time (independent variable). To incorporate the longitudinal nature of the data, a linear mixed effect model was fitted to the data with individuals added as a random effect to the model and time as the independent variable. This was undertaken using the lMERTEST package.
Results
Characteristics and risk factor trends of all new visual impairment certifications due to diabetic retinopathy There were 76 new visual impairment certifications with diabetic retinopathy and/or maculopathy documented as a primary or contributing cause between 2010 and 2013; on further review of case notes, one patient did not have a diagnosis of diabetes and was removed from further analysis; 52 of the CVIs were SI certifications and 23 were SSI certifications. The patient characteristics are summarized in Table 1 .
The mean duration of known diabetes at time of CVI was 22.0 years (36.8 years for T1DM, 16.9 years for T2DM, p < 8.7 9 10 À7 ). The male to female ratio in patients with CVI due to DR was 0.7:1.
Seven patients (9.3%) were not screened for retinopathy through the DR screening programme prior to CVI. Of these, four patients had previously undiagnosed diabetes and were not known to the screening programme before presenting to the hospital eye service with sight-threatening DR. Three patients were known to the screening programme; two had requested to be suspended from screening as they were already undergoing treatment and regular follow-up at their local hospital eye service, and one patient did not respond to multiple invitations to attend screening.
Seven patients were diagnosed with diabetes less than 2 years before CVI. There were two patients who were consecutively certified as SI followed by SSI during this 4-year period (1 after 0.38 years and the other after 2.14 years).
There was no significant difference between gender (p = 0.80), age at time of CVI (p = 0.12), type of diabetes (p = 0.09), duration of known diabetes (p = 0.20) and duration registered with the diabetic screening programme (p = 0.67) between the SI and SSI groups. Table 2 summarizes the last recorded IFCC-HbA1c, total cholesterol and creatinine in the 12 months prior to CVI.
Only 26 patients (39%) achieved a last recorded IFCC-HbA1c of 59 mmol/mol or less.
There was no significant difference between last measured IFCC-HbA1c (p = 0.364), total cholesterol (p = 0.2 73) and creatinine (p = 0.551) in the 12 months before CVI between the SI and SSI groups.
Linear regression analysis showing the trend in IFCC-HbA1c, total cholesterol and creatinine levels in the 5 years preceding CVI is shown in Retinopathy grading in the better seeing eye at the time of the last screen prior to CVI is summarized in Table 3 . There was no significant difference in the duration between CVI and last diabetic screening visit prior to CVI (p = 0.29) between the SI and SSI groups. Interestingly, three patients had a retinopathy grading of R0 in the better seeing eye prior to CVI. Further detailed case review revealed that two of these patients would have been graded as R3S (Stable Treated Proliferative Retinopathy) under the revised grading classification introduced in 2012 (NHS Diabetic Eye Screening Programme 2012). The third patient had been correctly graded as R0 at the time of screening, but later developed diabetic macular oedema while under regular hospital eye service review leading to a reduction in visual acuity.
Analysis of all new visual impairment certifications due to diabetic retinopathy
The annual incidence of CVIs due to DR per million population was calculated by taking the number of CVIs each year divided by the mid-year population estimates (for all ages) obtained from the UK Office for National Statistics (Table 4) .
The estimated number of people aged 16 years and above with both diagnosed and undiagnosed diabetes in Devon was obtained based on the Yorkshire and Humber Public Health Observatory (YHPHO) model, and this was used to calculate incidence of CVI due to DR per 1000 people aged 16 years and above with diabetes (Table 4 ). The incidence of CVI due to DR per million population per year, and the incidence of CVI due to DR per 1000 diabetic population (aged 16 years and above) per year, is shown in Table 4 . There was no significant increase or decrease in the incidence of CVI due to DR per million population (p = 0.136) or the incidence of CVI due to DR per 1000 diabetic population ages 16 years and above (p = 0.644) over the four years under study.
Analysis of all causes of visual impairment certification in 2013
For the period 1st January 2013 to 31st December 2013, there were 315 CVIs completed for patients from North and Eastern Devon region. The type of visual impairment was not completed for seven forms. Of the 308 completed forms, there were 180 SI certifications and 128 SSI certifications. The causes of visual impairment certification are summarized in Table 5 .
The leading cause of CVI was agerelated macular degeneration (41.3%), followed by glaucoma (7.6%) and congenital abnormalities of the eye (6%). Diabetic retinopathy (DR) and maculopathy accounted for 3.8% of all visual impairment certifications in 2013 and was the fourth most common primary cause of visual impairment, together with retinal vascular occlusions, optic atrophy and hereditary retinal disorders.
There were 15 SSI certifications in the working age population in 2013. The leading cause of SSI certification was optic atrophy (33.3%). Diabetic retinopathy (DR) or maculopathy did not contribute to any SSI certifications in this population, either as a primary cause or a contributing cause.
Discussion
Epidemiology studies have shown a strong association between visual impairment and duration of diabetes, and 25 years after diagnosis, the cumulative incidence of visual impairment in the diabetic population rises to 10-13% (Jeppesen & Bek 2004; Klein et al. 2010 ). In our study, the mean duration of known diabetes at the time of registration was almost 22 years, reflecting the slow development of sight-threatening retinopathy and visual loss. Acta Ophthalmologica 2017 T1DM patients are over-represented in the CVI cohort compared to the general diabetic population; 25% of patients had T1DM and 75% had T2DM; this differs significantly compared with the adult diabetic population where 10% of patients have T1DM and 90% have T2DM (p = 0.0085) (Diabetes UK 2012). This is likely secondary to the prolonged duration of the disease in patients with T1DM compared to T2DM.
Ten percent of patients were certified as visually impaired within 2 years of being diagnosed with diabetes, possibly presenting late to ophthalmic services with advanced retinopathy.
The estimated prevalence of diabetes in Devon is higher than the national average (7.8% versus 7.3% of the population aged 16 years and above) (Holman et al. 2011 ). In addition, North and Eastern Devon has an older population compared to national average, with 23.0% of the population aged 65 years and above compared with 17.4% of the population in England and Wales (Office for National Statistics. Population Estimates n.d.). It is therefore expected that the increased prevalence of diabetes in the region, combined with the increased duration of diabetes due to the ageing demographic, would result in a higher incidence of CVIs due to DR compared to the national average.
Our study has found, however, that the annual certification rate due to DR Nationwide, diabetic retinal screening was introduced between 2003 and 2008; however, Exeter has operated systematic diabetic retinal screening since 1992. We feel that the above results are consistent with the success of a long-standing retinal screening programme (Jacob et al. 1995) .
We are unsure as to the reasons behind the increase in number of CVIs completed in 2012 compared to the preceding two years. Certification is voluntary; the true rates of sight impairment and severe sight impairment in the community are likely to be higher than suggested by annual certification rates. It is unclear if the higher number of completed CVIs in that year represents a true increase in incidence or improved detection and recording. Analysis of retinopathy grading in the better seeing eye at the time of the last screen prior to CVI showed the presence of maculopathy in 70.8% of those subsequently certified as sight impaired but only in 47.0% of those subsequently certified as severely sight impaired. Although the numbers did not reach statistically significance (p = 0.138), it might suggest that visual impairment secondary to diabetic maculopathy might be less severe than that associated with complications of proliferative diabetic retinopathy, and potentially preventable with appropriate treatment. In recent years, NICE has issued guidance recommending several new treatment options for diabetic macular oedema, including intravitreal ranibizumab (Lucentis), intravitreal aflibercept (Eylea) and dexamethasone intravitreal implant (Ozurdex) (National Institute for Health and Care Excellence 2013, 2015a,b) , and it is expected that number of CVIs due to diabetic retinopathy and maculopathy will continue to fall in coming years. Indeed, the introduction of intravitreal ranibizumab as a treatment option for diabetic macular oedema in early 2013 could have contributed to the decrease in number of CVIs completed in our study in that year compared to the previous one.
Large studies have conclusively demonstrated the benefits of good glycaemic control in reducing the incidence of sight-threatening retinopathy (Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group 1995; Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group 1998). The National Institute for Health and Care Excellence (NICE) has issued guidelines for long-term glycaemic control derived from the results of these studies, with a recommended target DCCT-HbA1c level of less than 7.5% (or equivalent to an IFCC-HbA1c of less than 59 mmol/ mol) for patients with type 1 diabetes and a target DCCT-HbA1c level of less than 6.5% (or equivalent to an IFCCHbA1c of less than 48 mmol/mol) recommended for patients with type 2 diabetes (National Institute for Health and Care Excellence 2004, 2009 ). In our study group, only 39% of patients achieved target levels of IFCC-HbA1c of 59 mmol/mol or less in the 12 months preceding CVI, compared with 63% of the registered diabetic population in the same geographic catchment area in 2013/2014 (Health & Social Care Information Centre 2014) (p < 0.0001, chi-square without Yates correction), a difference that is statistically significant. This supports the finding that poor glycaemic control is an important and potentially modifiable risk factor for visual impairment in patients with diabetes. As the study was performed, NICE has since issued new guidelines with lower recommended target HbA1c levels of less than 6.5% (or 48 mmol/ mol) for patients with type 1 diabetes and less than 6.5-7.0% (or 48-53 mmol/mol) recommended for patients with type 2 diabetes (National Institute for Health and Care Excellence 2015c,d).
The study found a significant increasing trend in serum creatinine levels in the 5 years leading up to CVI. This is not surprising considering diabetic retinopathy and nephropathy share many common risk factors, such as duration of diabetes, poor glycaemic control and systemic hypertension, and indeed diabetic nephropathy has been positively associated with DR (Stratton et al. 2001; Boelter et al. 2006; AlRubeaan et al. 2015) . There was a significant, paradoxical trend in improvement of HbA1c in the 5 years leading up to CVI. Our results are consistent with previous reports of progression of DR when intensive glucose control is initiated, especially in patients with high initial HbA1c levels or pre-existing moderate to severe DR. Ophthalmological monitoring of such (Liew et al. 2014) . However, recent data from 2009 to 2010 suggest that for the first time, DR and maculopathy are now the second most common cause of blindness registrations behind hereditary retinal disorders, accounting for 14.1% of all blindness registrations in the working age group (Liew et al. 2014) . Our study found that while optic atrophy was the most common cause of SSI certification in the working age population in 2013, DR or maculopathy did not contribute to any SSI certifications in this population, either as a primary cause or a contributing cause. The average age of CVI due to DR in our population was 65.7 years, which is beyond the working age definition of 16 years to 64 years.
These findings likely reflect the success of a prolonged focus on the prevention and treatment of diabetic eye disease, achieved by a combination of the introduction of a nationwide DR screening service across England and Wales between 2003 and 2008 (NHS Diabetic Eye Screening Programme n.d.), as well as improvements in risk factor and glycaemic control in patients with diabetes (Oluwatowoju et al. 2010) . Improved diabetes control, either alone or in combination with the introduction of a DR screening programme, has also been credited with a decreased proportion of visual impairment in diabetic patients seen in several countries including Finland (Laatikainen et al. 2016) , Iceland (Stefansson et al. 2000) and the USA (Klein et al. 2010) . Delaying the development of sight impairment in people with diabetes allows them to continue working for longer and has a substantial impact on the socio-economic costs of the condition.
References
Al-Rubeaan K, Abu El-Asrar AM, Youssef AM et al. (2015) : Diabetic retinopathy and its risk factors in a society with a type 2 diabetes epidemic: a Saudi National Diabetes Registry-based study. Acta Ophthalmol 93: e140-e147. 
